Deborah G. Nguyen, PhD, joined the Accelerator in 2017 as Vice President of Research. Through her roles at portfolio companies Cellular Approaches, Anexigen and Calporta Therapeutics (acquired by Merck), Dr. Nguyen has helped guide the discovery and development of novel small molecules, peptides and cell-based therapies to combat bacterial infections and neurodegenerative diseases. Prior to joining the Accelerator, Dr. Nguyen spent 15 years enabling drug discovery and development in pharma and biotech environments. After earning her PhD, Deb spent ten years at the Genomics Institute of the Novartis Research Foundation (GNF) leading programs in autoimmunity / inflammation, metabolic disease and infectious disease from target validation to clinical candidate nomination. She then moved to Organovo as Senior Director of R&D, using the company’s proprietary bioprinting platform to create more predictive pre-clinical tissue models and helping build the commercial service organization. Those efforts led to the successful commercial launch of two patented engineered tissue products and subsequent peer reviewed publications describing their utility. Deb received her PhD in Pharmacology from the Johns Hopkins School of Medicine and a BS in Biochemistry from California State University, Los Angeles.